



PRESS RELEASE

Collectis to Report Third Quarter Financial Results on November 7, 2025

New York, NY - October 31, 2025 - Collectis (the "Company") (Euronext Growth: ALCLS-NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the third quarter 2025 ending September 30, 2025 on Friday, November 7, 2025 after the close of the US market.

The press release will be available in the Investors section of Collectis' website: <https://www.collectis.com/en/investors/press-releases/>

Collectis will not host a conference call to discuss these results. Our investors relations team remains available for questions at investors@collectis.com

About Collectis

Collectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Collectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish. Collectis' headquarters are in Paris, France, with locations in New York and Raleigh, NC. Collectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit www.collectis.com and follow Collectis on LinkedIn and X.

For further information on Collectis, please contact:

Media contacts:

Pascalyné Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@collectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93

Investor Relations contact:

Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@collectis.com